AI News
Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion
Generative AI startup Profluent signs a multi-billion dollar agreement to accelerate the design of custom gene editors.
Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion Reuters
RT
Reuters Technology
Source
Reuters Technology
AI Analysis
Generated insight by OnAirToday AI
This partnership highlights how generative AI is shifting from theoretical research to high-stakes drug discovery by designing custom proteins from scratch. By leveraging deep learning, these companies are significantly accelerating the identification of precise genetic therapies that were previously difficult to engineer.
Powered by AI • Not a substitute for human analysisMore Insights →
Share
Filed under:AI News

Comments
Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.